The effects of mild or moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of naloxegol

Journal of clinical pharmacology

Volumn 54, Issue 12, 2014, Pages 1368-1374

  Bui, Khanh ^a   She, Fahua ^a   Sostek, Mark ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

hepatic impairment; naloxegol; opioid receptor antagonist; opioid induced constipation; pharmacokinetics

Indexed keywords

MACROGOL DERIVATIVE; MORPHINAN DERIVATIVE; NALOXEGOL; NARCOTIC ANTAGONIST;

ADULT; AREA UNDER THE CURVE; BLOOD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LIVER DISEASE; MALE; METABOLISM; MIDDLE AGED;

ADULT; AREA UNDER CURVE; FEMALE; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; MORPHINANS; NARCOTIC ANTAGONISTS; POLYETHYLENE GLYCOLS;

EID: 84964315110     PISSN: None     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.348     Document Type: Article

References (0)